Mesenchymal stem cells and neurodegenerative disease

A L Whone; N J Scolding

doi:10.1038/clpt.2008.205

Mesenchymal stem cells and neurodegenerative disease

A L Whone, N J Scolding

Research output: Contribution to journal › Article (Academic Journal) › peer-review

10 Citations (Scopus)

Abstract

The prospect of cell therapy for incurable neurodegenerative disease excites scientists, the public, and patients alike. Clinical and scientific enthusiasm must, however, always be tempered by methodological rigor and by the overwhelming imperative of protecting vulnerable sufferers. We tentatively suggest that, in the case of autologous mesenchymal stem cells (MSCs), the balance between our current understanding of their biology and an informed assessment of their probable safety allows a case to be made for cautious pilot clinical studies.

Original language	English
Pages (from-to)	19-20
Number of pages	2
Journal	Clinical Pharmacology and Therapeutics
Volume	85
Issue number	1
DOIs	https://doi.org/10.1038/clpt.2008.205
Publication status	Published - 2009

Access to Document

10.1038/clpt.2008.205

Fingerprint Dive into the research topics of 'Mesenchymal stem cells and neurodegenerative disease'. Together they form a unique fingerprint.

Cite this

@article{700b4cf9fa694321ae3a8a2a784ae165,

title = "Mesenchymal stem cells and neurodegenerative disease",

abstract = "The prospect of cell therapy for incurable neurodegenerative disease excites scientists, the public, and patients alike. Clinical and scientific enthusiasm must, however, always be tempered by methodological rigor and by the overwhelming imperative of protecting vulnerable sufferers. We tentatively suggest that, in the case of autologous mesenchymal stem cells (MSCs), the balance between our current understanding of their biology and an informed assessment of their probable safety allows a case to be made for cautious pilot clinical studies.",

author = "Whone, {A L} and Scolding, {N J}",

year = "2009",

doi = "10.1038/clpt.2008.205",

language = "English",

volume = "85",

pages = "19--20",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Mesenchymal stem cells and neurodegenerative disease

AU - Whone, A L

AU - Scolding, N J

PY - 2009

Y1 - 2009

N2 - The prospect of cell therapy for incurable neurodegenerative disease excites scientists, the public, and patients alike. Clinical and scientific enthusiasm must, however, always be tempered by methodological rigor and by the overwhelming imperative of protecting vulnerable sufferers. We tentatively suggest that, in the case of autologous mesenchymal stem cells (MSCs), the balance between our current understanding of their biology and an informed assessment of their probable safety allows a case to be made for cautious pilot clinical studies.

AB - The prospect of cell therapy for incurable neurodegenerative disease excites scientists, the public, and patients alike. Clinical and scientific enthusiasm must, however, always be tempered by methodological rigor and by the overwhelming imperative of protecting vulnerable sufferers. We tentatively suggest that, in the case of autologous mesenchymal stem cells (MSCs), the balance between our current understanding of their biology and an informed assessment of their probable safety allows a case to be made for cautious pilot clinical studies.

U2 - 10.1038/clpt.2008.205

DO - 10.1038/clpt.2008.205

M3 - Article (Academic Journal)

C2 - 19092766

VL - 85

SP - 19

EP - 20

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -